PCA3 messenger RNA species in benign and malignant prostate tissues
View Patent ↗This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostrate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.
1. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule is associated with a non-malignant prostatic state.
2. An isolated nucleic acid molecule consisting of at least 12 nucleotides which specifically hybridizes to a PCA3 mRNA associated with a non-malignant prostatic state, wherein said isolated nucleic acid molecule is or is complementary to a nucleotide sequence comprising of at least 12 consecutive nucleotides from nucleotides 27 to 254 of SEQ ID NO:1.
3. A kit for detecting the presence of PCA3 mRNAs associated with a non-malignant prostatic state in a sample, comprising at least one container means having disposed therein the isolated nucleic acid molecule of claim 2 .
4. A recombinant nucleic acid molecule comprising, 5′ to 3′, a heterologous promoter effective to initiate transcription in a host cell and the isolated nucleic acid molecule of claim 1 .
5. An isolated cell that contains the recombinant nucleic acid molecule of claim 4 .
6. An isolated nucleic acid molecule comprising the nucleic acid sequence from nucleotides 27 to 254 of SEQ ID NO:1, wherein said isolated nucleic acid molecule is associated with a non-malignant prostatic state.
7. The isolated nucleic acid molecule of claim 2 , wherein said isolated nucleic acid molecule consists of the sequence of SEQ ID NO:4.
8. A recombinant nucleic acid molecule comprising, 5′ to 3′, a heterologous promoter effective to initiate transcription in a host cell and the isolated nucleic acid molecule of claim 6 .
9. An isolated cell that contains the recombinant nucleic acid molecule of claim 8 .
10. The isolated nucleic acid molecule of claim 2 , wherein said nucleic acid molecule consists of 15 to 50 nucleotides.
11. The isolated nucleic acid molecule of claim 2 , wherein said nucleic acid molecule consists of 18 to 50 nucleotides.
12. The isolated nucleic acid molecule of claim 2 , wherein said nucleic acid molecule consists of 20 to 50 nucleotides.
13. A kit for detecting the presence of differentially expressed PCA3 mRNAs in a sample comprising at least one container having disposed therein the isolated nucleic acid molecule of claim 10 .
14. A kit for detecting the presence of differentially expressed PCA3 mRNAs in a sample comprising at least one container having disposed therein the isolated nucleic acid molecule of claim 11 .
15. A kit for detecting the presence of differentially expressed PCA3 mRNAs in a sample comprising at least one container having disposed therein the isolated nucleic acid molecule of claim 12 .
16. The isolated nucleic acid molecule of claim 2 , wherein said nucleic acid molecule consists of 12 to 50 nucleotides.
17. The isolated nucleic acid molecule of claim 2 , wherein said nucleic acid molecule consists of 15 to 24 nucleotides.
18. A kit for detecting the presence of differentially expressed PCA3 mRNAs in a sample comprising at least one container having disposed therein the isolated nucleic acid molecule of claim 16 .
19. A kit for detecting the presence of differentially expressed PCA3 mRNAs in a sample comprising at least one container having disposed therein the isolated nucleic acid molecule of claim 17 .
20. The isolated nucleic acid molecule of claim 1 , wherein said non-malignant prostatic state is benign prostate hyperplasia.
21. The isolated nucleic acid molecule of claim 2 , wherein said non-malignant prostatic state is benign prostate hyperplasia.